Suppr超能文献

下肢慢性肢体威胁性缺血血运重建结局的系统评价和荟萃分析。

A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia.

机构信息

Evidence-Based Practice Research Program, Mayo Clinic, Rochester, Minn; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn.

Division of General Internal Medicine, Mayo Clinic, Rochester, Minn.

出版信息

J Vasc Surg. 2018 Aug;68(2):624-633. doi: 10.1016/j.jvs.2018.01.066. Epub 2018 May 24.

Abstract

BACKGROUND

The optimal strategy for revascularization in infrainguinal chronic limb-threatening ischemia (CLTI) remains debatable. Comparative trials are scarce, and daily decisions are often made using anecdotal or low-quality evidence.

METHODS

We searched multiple databases through May 7, 2017, for prospective studies with at least 1-year follow-up that evaluated patient-relevant outcomes of infrainguinal revascularization procedures in adults with CLTI. Independent pairs of reviewers selected articles and extracted data. Random-effects meta-analysis was used to pool outcomes across studies.

RESULTS

We included 44 studies that enrolled 8602 patients. Periprocedural outcomes (mortality, amputation, major adverse cardiac events) were similar across treatment modalities. Overall, patients with infrapopliteal disease had higher patency rates of great saphenous vein graft at 1 and 2 years (primary: 87%, 78%; secondary: 94%, 87%, respectively) compared with all other interventions. Prosthetic bypass outcomes were notably inferior to vein bypass in terms of amputation and patency outcomes, especially for below knee targets at 2 years and beyond. Drug-eluting stents demonstrated improved patency over bare-metal stents in infrapopliteal arteries (primary patency: 73% vs 50% at 1 year), and was at least comparable to balloon angioplasty (66% primary patency). Survival, major amputation, and amputation-free survival at 2 years were broadly similar between endovascular interventions and vein bypass, with prosthetic bypass having higher rates of limb loss. Overall, the included studies were at moderate to high risk of bias and the quality of evidence was low.

CONCLUSIONS

There are major limitations in the current state of evidence guiding treatment decisions in CLTI, particularly for severe anatomic patterns of disease treated via endovascular means. Periprocedural (30-day) mortality, amputation, and major adverse cardiac events are broadly similar across modalities. Patency rates are highest for saphenous vein bypass, whereas both patency and limb salvage are markedly inferior for prosthetic grafting to below the knee targets. Among endovascular interventions, percutaneous transluminal angioplasty and drug-eluting stents appear comparable for focal infrapopliteal disease, although no studies included long segment tibial lesions. Heterogeneity in patient risk, severity of limb threat, and anatomy treated renders direct comparison of outcomes from the current literature challenging. Future studies should incorporate both limb severity and anatomic staging to best guide clinical decision making in CLTI.

摘要

背景

在下肢慢性肢体严重缺血(CLTI)患者中,血运重建的最佳策略仍存在争议。比较性试验较少,日常决策通常基于轶事或低质量的证据。

方法

我们通过 2017 年 5 月 7 日检索多个数据库,以评估 CLTI 成人下肢血运重建术患者相关结局为目的,纳入至少随访 1 年的前瞻性研究。独立的评审员 pairs 对文章进行筛选并提取数据。使用随机效应荟萃分析对研究结果进行汇总。

结果

我们纳入了 44 项研究,共 8602 名患者。围手术期结局(死亡率、截肢率、重大心脏不良事件)在不同治疗方法之间相似。总体而言,与所有其他干预措施相比,大隐静脉移植物在 1 年和 2 年时的通畅率更高(一级通畅率:87%,78%;二级通畅率:94%,87%)。人造旁路的结局明显劣于静脉旁路,特别是在 2 年及以后的膝下靶目标。药物洗脱支架在治疗下肢动脉病变方面优于裸金属支架(1 年时一级通畅率:73% vs 50%),并且至少与球囊血管成形术相当(66%的一级通畅率)。2 年时的生存、主要截肢和无截肢生存率在血管内介入治疗和静脉旁路之间大致相似,但人造旁路的肢体丧失率更高。总体而言,纳入的研究存在中度至高度偏倚风险,证据质量较低。

结论

目前在 CLTI 治疗决策中指导治疗的证据存在重大局限性,特别是对于通过血管内方法治疗的严重解剖病变模式。围手术期(30 天)死亡率、截肢率和重大心脏不良事件在各种方法之间大致相似。大隐静脉旁路的通畅率最高,而人造移植物在膝下靶目标的通畅率和保肢率均明显降低。在血管内介入治疗中,经皮腔内血管成形术和药物洗脱支架似乎对下肢动脉的局灶性病变相当,尽管没有研究纳入长段胫骨病变。患者风险、肢体威胁严重程度和治疗解剖的异质性使得难以直接比较当前文献中的结果。未来的研究应结合肢体严重程度和解剖分期,以最佳指导 CLTI 的临床决策。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验